期刊
SCIENCE
卷 334, 期 6059, 页码 1129-1133出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1206727
关键词
-
资金
- Multiple Myeloma Research Foundation
- American Cancer Society [121360-PF-11-256-01-TBG]
- Dana-Farber Cancer Institute
- Gabrielle's Angel Foundation for Cancer Research
- FLAMES Fund of the Pan-Mass Challenge
- NIH [RO1CA129974, P01CA068484, P01CA139980]
Cytotoxic chemotherapy targets elements common to all nucleated human cells, such as DNA and microtubules, yet it selectively kills tumor cells. Here we show that clinical response to these drugs correlates with, and may be partially governed by, the pretreatment proximity of tumor cell mitochondria to the apoptotic threshold, a property called mitochondrial priming. We used BH3 profiling to measure priming in tumor cells from patients with multiple myeloma, acute myelogenous and lymphoblastic leukemia, and ovarian cancer. This assay measures mitochondrial response to peptides derived from proapoptotic BH3 domains of proteins critical for death signaling to mitochondria. Patients with highly primed cancers exhibited superior clinical response to chemotherapy. In contrast, chemoresistant cancers and normal tissues were poorly primed. Manipulation of mitochondrial priming might enhance the efficacy of cytotoxic agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据